Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Galderma’s 2.6 B CHF Share Sale Fuels Growth, Boosts R&D & M&A Potential

Galderma’s 2.6 billion‑CHF share sale fuels R&D, market expansion, and strategic M&A while keeping stock above the offer price, showcasing strong investor confidence and growth potential in dermatology and aesthetic medicine.

Lisa Martinez

31/10/2025, 09:33

4 minutes to read

Sanofi’s Q3 Earnings Boosted by Dupixent Success, Positive Outlook for 2025-2026

Sanofi’s third-quarter earnings report exceeded expectations, driven by strong sales of its flagship product Dupixent, which surpassed €4 billion in revenue for the first time, and the company reaffirmed its 2025 outlook while signaling optimism f…

Lisa Martinez

24/10/2025, 10:15

4 minutes to read

Lonza Group AG Stands Firm Amid SMI Downturn, Bolstered by Strategic Position in Biopharmaceuticals

Lonza Group AG’s share price remained stable despite a modest decline in the Swiss Market Index, reflecting investor confidence in the company’s strategic positioning and robust business model in the biopharmaceutical and nutritional sectors.

Lisa Martinez

22/10/2025, 11:44

3 minutes to read

Bristol-Myers Squibb Sees Share Rally Amid Pipeline Optimism and Strategic Initiatives

Bristol-Myers Squibb’s share price has rallied due to expectations of continued revenue growth from its oncology and immunology pipeline, driven by proactive market-access initiatives and a balanced mix of high-margin and high-risk projects.

Lisa Martinez

22/10/2025, 11:13

3 minutes to read

Sartorius AG’s Share Price Soars Amid Strong Financial Results and Strategic Market Moves

Sartorius AG, a German specialist in life-science equipment, has seen a significant rise in its share price due to robust quarterly financial results, a positive outlook from US counterpart firms, and its successful market-access strategy, niche spe…

Lisa Martinez

22/10/2025, 07:40

5 minutes to read

Genmab’s Rina-S Advances in Endometrial Cancer Treatment with FDA Breakthrough Designation

Genmab A/S, a Danish biotech company, is poised for commercial success with its bispecific antibody Rina-S, which has shown impressive early-stage clinical results in advanced endometrial cancer and has received Breakthrough Therapy Designation from…

Lisa Martinez

19/10/2025, 12:15

4 minutes to read

Merck KGaA Navigates U.S. Pricing Policies with Strategic Agreements Amid Tariff Concerns

Merck KGaA has entered into two pricing-related agreements with the US government to maintain its market share and avoid tariff exposure, while also positioning itself for future growth through investments in next-generation fertility therapies and …

Lisa Martinez

19/10/2025, 07:24

3 minutes to read

Roche Advances in Oncology and Rare Diseases Amid Market Challenges and Strategic M&A Moves

Roche Holding AG has announced several strategic milestones, including positive clinical trial results, licensing agreements, and regulatory approvals, positioning the company for long-term growth in the competitive pharmaceutical and biotechnology …

Lisa Martinez

18/10/2025, 13:12

4 minutes to read

Merck’s New HIV Therapy Promises Cost Savings and Market Confidence with Innovative Two-Drug Regimen

Merck & Co Inc has reported positive data for its two-drug HIV regimen, doravirine and islatravir, which demonstrates non-inferiority to a leading single-tablet regimen and offers a potential cost-saving advantage for payers.

Lisa Martinez

16/10/2025, 09:25

4 minutes to read

Chugai Pharmaceutical Faces Market Challenges Amidst Roche’s Diagnostic Innovations and Patent Cliff Pressures

Chugai Pharmaceutical Co. Ltd. faces challenges in the Japanese equity market, but its long-term commercial viability can be safeguarded through proactive market access planning, strategic partnerships, and a diversified portfolio.

Lisa Martinez

14/10/2025, 09:43

4 minutes to read

Newer articles Older articles